# Sudeep Pharma (NSE: SUDEEPPHRM) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/SUDEEPPHRM · Pivot · prices to 22 Oct 2026

Sudeep Pharma (NSE: SUDEEPPHRM) closed at ₹984.90 on 22 Oct 2026, up 1.02% on the day. With a market capitalisation of ₹11,124 Cr, it ranks 528th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 66.2× trailing earnings, against a return on equity of 19.6% in FY26. Its 52-week range is ₹524.05 (21 Jan 2026) to ₹1,378.00 (7 Sep 2026); the last close is 28.5% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹158 Cr (+26.7% year on year) and net profit ₹41 Cr (+29.8%), on a consolidated basis. Promoters held 76.15% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹984.90 |
| Market cap | ₹11,124 Cr |
| P/E (trailing) | 66.2 |
| ROE | 19.6% (FY26) |
| ROCE | 24.2% (FY26) |
| Debt to equity | 0.17 |
| 52-week high | ₹1,378.00 (7 Sep 2026) |
| 52-week low | ₹524.05 (21 Jan 2026) |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹158 Cr | +26.7% | ₹41 Cr | +29.8% | ₹3.59 |
| Q4 FY26 | ₹182 Cr | +15.7% | ₹49 Cr | +9.8% | ₹4.38 |
| Q3 FY26 | ₹172 Cr | +49.2% | ₹48 Cr | +66.1% | ₹4.29 |
| Q2 FY26 | ₹163 Cr | — | ₹47 Cr | — | ₹4.20 |
| Q1 FY26 | ₹125 Cr | — | ₹31 Cr | — | ₹2.80 |
| Q4 FY25 | ₹158 Cr | — | ₹44 Cr | — | ₹4.07 |
| Q3 FY25 | ₹116 Cr | — | ₹29 Cr | — | ₹2.65 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹502 Cr | ₹139 Cr |
| FY24 | ₹459 Cr | ₹133 Cr |
| FY23 | ₹429 Cr | ₹62 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 76.15%
- Foreign institutions: 1.81%
- Domestic institutions: 15.65%
- Non-institutions: 6.39%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [CORONA Remedies](https://app.pivotnow.in/stock/CORONA) | ₹2,024.70 | ₹12,383 Cr | 66.8 | — |
| [Rainbow Childrens Medicare](https://app.pivotnow.in/stock/RAINBOW) | ₹1,205.70 | ₹12,245 Cr | 43.9 | — |
| [Metropolis Healthcare](https://app.pivotnow.in/stock/METROPOLIS) | ₹532.25 | ₹11,035 Cr | 57.9 | — |
| [Akums Drugs and Pharmaceuticals](https://app.pivotnow.in/stock/AKUMS) | ₹690.85 | ₹10,874 Cr | 41.5 | — |
| [Park Medi World](https://app.pivotnow.in/stock/PARKHOSPS) | ₹220.45 | ₹9,522 Cr | 32.1 | — |
| [Blue Jet Healthcare](https://app.pivotnow.in/stock/BLUEJET) | ₹499.60 | ₹9,456 Cr | 35 | — |

## Questions and answers

### What is the share price of Sudeep Pharma today?

Sudeep Pharma (NSE: SUDEEPPHRM) last closed at ₹984.90 on 22 Oct 2026. Its 52-week high is ₹1,378.00 and its 52-week low is ₹524.05.

### What is the market cap of Sudeep Pharma?

Sudeep Pharma's market capitalisation is ₹11,124 Cr (₹11,124 Cr) at the 22 Oct 2026 close, ranking 528th among the NSE companies Pivot tracks.

### What is the P/E ratio of Sudeep Pharma?

Sudeep Pharma trades at a trailing P/E of 66.2. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 43.9.

### What is the ROE and ROCE of Sudeep Pharma?

Return on equity was 19.6% in FY26 and return on capital employed was 24.2% in FY26 (consolidated figures).

### Is Sudeep Pharma a debt-free company?

No. Sudeep Pharma's debt-to-equity ratio was 0.17 in FY26, with total debt of ₹34 Cr.

### What were Sudeep Pharma's latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), Sudeep Pharma reported revenue of ₹158 Cr, +26.7% year on year, and net profit of ₹41 Cr, +29.8% year on year.

### What is the shareholding pattern of Sudeep Pharma?

As of 30 Jun 2026: promoters 76.15%, foreign institutions 1.81%, domestic institutions 15.65%, non-institutions 6.39%.

### Who are Sudeep Pharma's competitors?

The listed Pharma & Healthcare companies closest to Sudeep Pharma by market cap are CORONA Remedies, Rainbow Childrens Medicare, Metropolis Healthcare, Akums Drugs and Pharmaceuticals, Park Medi World and Blue Jet Healthcare.

### Is Sudeep Pharma a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Sudeep Pharma's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on SUDEEPPHRM against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.